Log in

NASDAQ:LOGCLogicBio Therapeutics Stock Price, Forecast & News

$7.86
-0.06 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.67
Now: $7.86
$8.04
50-Day Range
$7.33
MA: $8.22
$9.10
52-Week Range
$3.05
Now: $7.86
$14.00
Volume40,189 shs
Average Volume74,286 shs
Market Capitalization$184.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share

Profitability

Net Income$-40,130,000.00

Miscellaneous

Employees23
Market Cap$184.16 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable
$7.86
-0.06 (-0.76 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LOGC shares have increased by 11.6% and is now trading at $7.86.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for LogicBio Therapeutics
.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for LogicBio Therapeutics
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.07. The firm had revenue of $1.02 million for the quarter.
View LogicBio Therapeutics' earnings history
.

What price target have analysts set for LOGC?

2 analysts have issued 12-month price objectives for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate LogicBio Therapeutics' share price to reach $20.00 in the next year. This suggests a possible upside of 154.5% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
.

Has LogicBio Therapeutics been receiving favorable news coverage?

News headlines about LOGC stock have trended extremely negative this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. LogicBio Therapeutics earned a news sentiment score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about LogicBio Therapeutics
.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 205,500 shares, an increase of 17.3% from the July 15th total of 175,200 shares. Based on an average daily trading volume, of 62,100 shares, the short-interest ratio is currently 3.3 days. Approximately 1.3% of the company's shares are short sold.
View LogicBio Therapeutics' Short Interest
.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Acceleron Pharma (XLRN), Alector (ALEC), Gossamer Bio (GOSS), Crispr Therapeutics (CRSP), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK), Tcr2 Therapeutics (TCRR), AbbVie (ABBV) and Akero Therapeutics (AKRO).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Who are LogicBio Therapeutics' major shareholders?

LogicBio Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.06%).
View institutional ownership trends for LogicBio Therapeutics
.

Which major investors are buying LogicBio Therapeutics stock?

LOGC stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP.
View insider buying and selling activity for LogicBio Therapeutics
.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $7.86.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $184.16 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.